common
featur
asthma
copd
import
role
infect
trigger
exacerb
infect
also
implic
etiolog
two
diseas
chapter
review
epidemiolog
evid
implic
infecti
pathogen
trigger
discuss
mechan
interact
hostpathogen
respons
preexist
airway
patholog
result
exacerb
asthma
affect
children
uk
multifacet
syndrom
involv
atopi
bronchial
hyperreact
ige
nonig
mediat
acut
chronic
immun
respons
asthmat
airway
character
infiltr
eosinophil
lymphocyt
express
type
cytokin
trigger
factor
associ
acut
exacerb
asthma
includ
exposur
environment
allergen
especi
anim
mold
pollen
mite
cold
exercis
drugsth
link
respiratori
infect
asthma
exacerb
well
establish
although
incomplet
understood
associ
attribut
bacteri
allergi
clear
major
exacerb
due
viral
rather
bacteri
infect
viral
respiratori
tract
infect
major
caus
wheez
infant
adult
patient
asthma
role
may
underestim
earli
epidemiolog
studi
difficulti
isol
identif
introduct
pcr
studi
implic
viral
infect
major
asthma
exacerb
indirect
evid
popul
studi
establish
signific
correl
season
variat
wheez
episod
young
children
peak
viru
identif
season
pattern
identif
respiratori
virus
associ
peak
hospit
admiss
children
adult
asthma
indic
role
infect
sever
asthma
attack
direct
evid
implic
viral
infect
asthma
exacerb
provid
studi
show
increas
rate
viru
detect
individu
suffer
asthma
attack
virus
detect
asthma
exacerb
children
adult
highest
rate
identif
studi
subject
follow
prospect
allow
collect
clinic
specimen
earli
cours
ill
pcrbase
method
diagnosi
use
addit
serolog
cultur
methodolog
use
allow
detect
rhinovirus
rate
detect
virus
exacerb
individu
asymptomat
order
contrast
studi
transtrach
aspir
adult
asthmat
exacerb
yield
spars
bacteri
cultur
correl
clinic
ill
differ
normal
subject
almost
studi
asthmat
predomin
virus
rhinovirus
rv
rsv
parainfluenza
virus
rv
alon
detect
around
virusinduc
asthma
attack
adenovirus
enterovirus
coronavirus
also
detect
less
frequent
influenza
found
annual
epidem
effect
respiratori
viru
infect
nasal
mucosa
upper
respiratori
tract
extens
investig
recent
effect
virus
lower
respiratori
tract
studi
detail
knowledg
pathogenet
mechan
involv
remain
limit
experiment
respiratori
viru
infect
human
volunt
limit
concern
safeti
studi
therefor
focus
experiment
innocul
rhinoviru
allerg
rhinit
mild
asthmat
individu
normal
control
subject
studi
provid
use
model
natur
viru
infect
asthma
offer
advantag
patient
select
monitor
control
condit
infect
rvinduc
effect
includ
asthma
symptomatolog
chang
use
medic
lung
function
airway
pathologyimmunolog
gener
clinic
physiolog
cellular
respons
experiment
rv
infect
asthma
rel
mild
necessarili
mimic
exactli
event
natur
common
cold
suggest
requir
complex
model
includ
viru
infect
preexist
increas
allerg
airway
inflamm
inde
recent
epidemiolog
evid
confirm
synergist
interact
viru
infect
allergen
exposur
precipit
hospit
admiss
asthma
trigger
factor
may
interact
infect
includ
air
pollut
studi
asthmat
children
demonstr
increas
risk
develop
asthmat
episod
within
day
upper
respiratori
tract
infect
nitrogen
dioxid
level
greater
lgm
studi
experiment
viru
infect
allerg
subject
perform
outsid
relev
season
allergen
exposur
one
recent
attempt
provid
model
combin
allergen
exposur
viru
infect
util
rv
infect
subject
allerg
rhiniti
individu
receiv
three
highdos
allergen
challeng
week
prior
innocul
tri
mimic
combin
allergen
exposur
viru
infect
interestingli
prior
allergen
challeng
model
somewhat
unexpectedli
appear
protect
rv
cold
delay
nasal
leukocytosi
delay
rise
proinflammatori
cytokin
delay
less
sever
clinic
cours
invers
correl
nasal
lavag
eosinophilia
sever
cold
symptom
explan
propos
author
studi
limit
highdos
allergen
challeng
may
reproduc
effect
chronic
lowdos
allergen
exposur
may
stimul
product
antiinflammatori
mediat
antivir
cytokin
ifnc
tnfa
develop
model
combin
allergen
exposur
viru
infect
clearli
requir
interact
respiratori
viru
infect
chronic
asthmat
airway
inflamm
result
respiratori
symptom
sever
suffer
nonasthmat
individu
detail
immunolog
mechan
underli
interact
current
unclear
current
hypothes
pathogenesi
virusinduc
asthma
exacerb
summar
tabl
diseas
syndrom
follow
infect
viru
consequ
direct
harm
effect
viru
immunopatholog
result
hostimmun
respons
asthmat
individu
exacerb
may
occur
function
interact
viral
patholog
asthmat
patholog
ie
differ
mechan
end
effect
function
share
pathogenet
mechan
addit
even
synergist
fashion
preexist
asthmat
inflamm
might
interfer
effect
antivir
respons
thu
allow
viru
caus
increas
airway
damag
altern
viru
infect
might
increas
sensit
asthmat
airway
trigger
factor
allergen
exposur
fact
like
virusinduc
asthma
exacerb
occur
combin
type
interact
increas
sever
symptom
includ
lower
respiratori
symptom
seen
subject
allerg
rhiniti
without
asthma
viral
infect
suggest
atop
phenotyp
import
determin
clinic
syndrom
follow
infect
respiratori
virus
altern
possibl
viru
infect
way
amplifi
subclin
allerg
lower
airway
inflamm
alreadi
present
prior
infect
tabl
summar
current
hypothes
propos
explain
mechan
exacerb
asthma
follow
respiratori
viru
infect
evid
support
hypothes
review
detail
wherea
respiratori
virus
influenza
parinfluenza
rsv
adenoviru
well
recogn
caus
lower
airway
syndrom
pneumonia
bronchiol
capabl
replic
lower
airway
recent
uncertainti
whether
rv
infect
occur
lower
airway
well
upper
respiratori
tract
although
possibl
nasopharyng
contamin
rule
rv
detect
lower
airway
clinic
specimen
sputum
tracheal
brush
bal
rtpcr
cultur
rv
asthma
chronic
obstruct
pulmonari
diseas
replic
demonstr
primari
cultur
bronchial
epitheli
cell
prefer
rv
cultur
c
rather
c
use
argument
lower
airway
infect
evid
replic
occur
lower
airway
temperatur
final
use
situ
hybrid
demonstr
rv
bronchial
biopsi
subject
follow
experiment
infect
data
confirm
rv
infect
lower
airway
occur
directli
implic
lower
airway
infect
pathogenesi
asthma
exacerb
subject
asthma
andor
allerg
rhiniti
exhibit
increas
pathophysiolog
effect
result
rv
infect
compar
nonatop
nonasthmat
control
detail
monitor
possibl
detect
reduct
peak
flow
home
record
fev
atop
asthmat
patient
acut
phase
experiment
infect
enhanc
sensit
histamin
allergen
challeng
innocul
nonasthmat
atop
rhinit
subject
increas
asthma
symptom
coincid
increas
maxim
bronchoconstrict
respons
methacholin
day
infect
signific
increas
sensit
histamin
asthmat
subject
infect
pronounc
sever
cold
symptom
respiratori
virus
enter
replic
within
epitheli
cell
line
lower
airway
entri
depend
interact
specif
receptor
exampl
adhes
molecul
case
major
group
rhinovirus
ldl
receptor
case
minor
group
rhinovirus
influenza
virus
bind
sialic
acid
residu
via
hemaglutinin
extent
epitheli
cell
destruct
observ
airway
vari
accord
viru
type
influenza
typic
caus
extens
necrosi
wherea
rv
caus
littl
patchi
damag
destruct
epitheli
cell
result
increas
epitheli
permeabl
increas
penetr
irrit
allergen
exposur
extens
network
affer
nerv
fibersthes
effect
may
contribut
increas
bronchial
hyperrespons
induc
viru
infect
increas
evid
epithelium
simpli
act
physic
barrier
import
regulatori
role
epitheli
cell
contribut
immun
respons
follow
viru
infect
product
cytokin
chemokin
fig
may
also
act
antigen
present
cell
particularli
secondari
respiratori
viral
infect
epitheli
cell
express
mhc
class
costimulatori
molecul
express
upregul
vitro
inflamm
central
event
asthma
viral
infect
process
involv
includ
interact
cascad
complement
coagul
fibrinolyt
kinin
system
plasma
well
cellderiv
cytokin
chemokin
arachidon
acid
metabolit
understand
interact
virus
cascad
asthma
incomplet
like
differ
virus
interact
system
differ
extent
howev
reason
believ
case
multitud
inflammatori
mediat
gener
act
epitheli
surfac
bradykinin
amino
acid
peptid
gener
plasma
precursor
part
inflammatori
process
shown
present
nasal
secret
rvinfect
individu
bradykinin
given
intranas
abl
reproduc
symptom
common
cold
sore
throat
rhiniti
although
presenc
kinin
lung
virusinfect
individu
report
present
upper
lower
airway
allerg
reaction
virus
may
also
caus
complementmedi
damag
complement
compon
bind
epitheli
cell
vitro
vivo
rsv
infect
increas
human
volunt
infect
influenza
viru
produc
divers
sourc
includ
epitheli
endotheli
smooth
muscl
cell
human
airway
appear
import
relax
human
airway
smooth
muscl
experiment
anim
parainfluenza
virusinduc
hyperreact
correl
defici
constitut
product
hand
inflam
tissu
react
superoxid
anion
gener
peroxynitrit
highli
toxic
compound
suggest
dual
role
mediat
increas
level
exhal
found
nonasthmat
volunt
follow
natur
cold
well
asthmat
patient
experiment
rv
infect
latter
studi
invers
associ
increas
worsen
airway
hyperrespons
demonstr
argu
favor
protect
role
substanc
support
observ
reduc
cytokin
product
viral
replic
vitro
model
rv
infect
upregul
asthmat
airway
one
explan
increas
sever
rv
infect
rv
shown
upregul
bronchial
biopsi
follow
experiment
rv
infect
nasal
epitheli
cell
obtain
brush
atop
subject
basal
level
increas
rel
nonatop
subject
elev
relev
season
peak
allergen
exposur
nasal
epitheli
cell
atop
subject
show
upregul
vitro
cultur
allergen
highest
basal
level
express
found
nasal
polyp
epitheli
cell
increas
infect
viral
titer
recov
infect
significantli
higher
polyp
epitheli
cell
nonatop
atop
nonpolyp
epitheli
cell
vitro
rv
increas
express
cultur
primari
bronchial
epitheli
cell
respiratori
epitheli
cell
line
via
mechan
involv
transcript
factor
nfjb
inhibit
upregul
might
expect
modifi
favor
cours
rv
infect
one
effect
corticosteroid
inhibit
nfjb
cell
primari
bronchial
epitheli
cell
pretreat
three
differ
corticosteroid
hydrocortison
dexamethason
mometason
furoat
inhibit
increas
surfac
express
mrna
promot
activ
without
alter
viru
infect
replic
disappointingli
studi
inhal
corticosteroid
asthmat
prior
experiment
rv
infect
fail
show
reduct
virusinduc
express
bronchial
biopsi
possibl
longer
cours
andor
higher
dose
inhal
steroid
administr
oral
steroid
might
demonstr
signific
effect
viral
infect
respiratori
tract
result
signific
chang
pattern
cytokin
express
number
cell
type
cell
immun
system
may
increas
number
activ
statu
cell
often
consid
structur
fact
contribut
significantli
immun
respons
epitheli
cell
effici
orchestr
immun
respons
cytokin
essenti
erad
viru
modif
cytokin
express
airway
may
contribut
increas
sever
viru
infect
asthma
vitro
studi
bronchial
epitheli
cell
line
demonstr
product
wide
rang
proinflammatori
cytokin
ifna
ifnc
tnfa
gmcsf
chemokin
rant
respons
rv
rsv
vivo
cytokin
found
nasal
lavag
associ
rv
infect
specif
role
individu
cytokin
human
lower
airway
viral
infect
well
understood
increas
inform
becom
avail
tnfa
share
proinflammatori
properti
induct
acut
phase
respons
activ
b
lymphocyt
enhanc
adhes
inflammatori
cell
endothelium
facilit
chemotaxi
tnfa
potent
antivir
cytokin
vitro
increas
suscept
cultur
epitheli
cell
infect
major
group
rhinoviru
upregul
shown
stimul
igamedi
immun
respons
may
also
import
virusinduc
asthma
appear
caus
bronchoconstrict
direct
effect
bronchial
smooth
muscl
vivo
elev
nasal
aspir
children
cold
level
correl
presenc
wheez
similarli
chemokin
increas
nasal
secret
natur
viral
exacerb
asthma
viral
upregul
cytokin
may
mediat
certain
key
transcript
factor
increas
product
cultur
epitheli
cell
due
rv
depend
nfjb
induct
tnfa
rsv
effect
virus
airway
smooth
muscl
cell
studi
util
isol
rabbit
tissu
human
cultur
airway
smooth
muscl
cell
suggest
exposur
viru
may
direct
effect
smooth
muscl
cell
result
increas
contractil
acetylcholin
impair
relax
isoproterenolthi
effect
depend
appear
involv
autocrin
signal
mechan
includ
upregul
product
airway
smooth
muscl
whether
rhinoviru
reach
airway
smooth
muscl
cell
suffici
quantiti
produc
signific
effect
mechan
vivo
yet
unknown
effect
respiratori
virus
smooth
muscl
requir
investig
varieti
leucocyt
show
chang
number
site
accumul
activ
state
respons
viru
infect
sinc
cell
also
implic
asthmat
inflamm
lower
airway
provid
potenti
site
interact
immunopatholog
viru
infect
asthma
alveolar
macrophag
present
larg
number
lower
airway
make
around
cell
seen
bal
normal
volunt
ideal
place
earli
phagocytosi
viru
particl
like
play
import
role
immun
respons
antigen
present
cell
product
cytokin
mediat
rv
shown
enter
human
monocyt
macrophag
express
high
level
major
rv
receptor
possibl
demonstr
rv
replic
within
alveolar
macrophag
although
low
grade
product
infect
shown
monocyt
cell
line
entri
monocyt
result
activ
product
tnfa
similarli
infect
human
monocyt
vitro
influenza
caus
alter
structur
activ
statu
product
tnfa
ifna
ifnb
effect
dramat
potenti
subsequ
exposur
bacteri
lp
dendrit
cell
key
cell
antigen
present
allergen
pathogen
capac
induc
primari
immun
respons
may
also
play
role
regul
type
cellmedi
immun
respons
increas
knowledg
immunobiolog
cell
well
studi
context
viral
exacerb
asthma
bronchial
biopsi
demonstr
increas
cell
posit
within
epithelium
submucosa
normal
asthmat
subject
follow
experiment
rv
infect
increas
coincid
peripher
lymphopenia
suggest
increas
recruit
cell
airway
although
altern
mechan
reduc
apoptosi
might
also
contribut
sinc
cell
believ
key
cell
pathogenesi
asthma
effect
virus
cell
particular
import
normal
cell
respons
viru
infect
thought
gener
helper
type
major
type
cytokin
ifnc
addit
ifna
ifnb
monocyt
macrophag
play
role
establish
antivir
state
neighbor
cell
ifnc
vari
effect
pathogenesi
asthma
appear
increas
basophil
mast
cell
histamin
releas
hand
inhibit
express
type
cytokin
product
ifnc
increas
pbmc
nasal
secret
rv
cold
human
anim
model
influenza
parainfluenza
rsv
infect
asthma
believ
character
inflamm
mani
studi
demonstr
mutual
inhibit
cell
therefor
possibl
within
airway
preexist
allerg
asthmat
microenviron
may
inhibit
normal
effect
antivir
immun
respons
respons
may
skew
toward
inappropri
potenti
harm
type
fig
recent
studi
experiment
infect
subject
allerg
rhiniti
asthma
balanc
airway
type
type
cytokin
sputum
induc
viral
infect
found
relat
clinic
symptom
viral
clearanc
although
protein
could
detect
sputum
due
presenc
inhibitor
elisa
assay
use
increas
mrna
determin
semiquantit
rtpcr
ifnc
invers
correl
demonstr
ratio
ifnc
mrna
mrna
peak
cold
symptom
addit
subject
still
detect
day
inocul
lower
ratio
acut
phase
cold
subject
clear
viru
cell
import
effector
cell
specif
cellmedi
antivir
immun
cell
also
demonstr
polar
cytokin
product
major
cytokin
produc
cell
ifnc
believ
play
role
regul
balanc
murin
model
asthma
induct
bystand
immun
respons
ovalbumin
result
switch
viruspeptidespecif
cell
lung
product
cytokin
includ
challeng
viru
peptid
induct
airway
eosinophilia
mechan
occur
man
would
suggest
mean
wherebi
antivir
function
could
inhibit
time
amplif
allerg
inflamm
induct
airway
eosinophilia
recruit
cell
blood
airway
least
part
influenc
chemokin
includ
whose
product
epitheli
cell
upregul
follow
viru
infect
cell
appear
show
differenti
express
chemokin
receptor
studi
cell
clone
demonstr
increas
express
receptor
itac
mig
human
cell
increas
express
tarc
mdc
lesser
extent
eotaxin
cell
select
migrat
cell
respons
appropri
chemokin
rant
found
cell
bronchial
biopsi
asthmat
show
high
level
express
signific
level
cell
increas
recruit
cell
airway
result
virusinduc
chemokin
product
epitheli
cell
could
amplifi
preexist
allerg
inflamm
asthmat
airway
microenviron
influenc
pattern
chemokin
express
follow
viru
infect
could
alter
balanc
antivir
immun
respons
cell
import
sourc
inflammatori
mediat
characterist
allerg
inflamm
asthma
mast
cell
basal
stimul
histamin
releas
increas
viru
infect
airway
mast
cell
number
upregul
rat
model
parainfluenza
infect
sever
virus
enhanc
basophil
igemedi
histamin
releas
role
cell
human
asthma
controversi
mast
cell
also
import
sourc
inflammatori
mediat
function
local
suggest
earli
interact
virus
ltc
among
major
mediat
respons
late
phase
bronchospasm
asthma
rsv
infect
increas
level
ltc
found
nasopharyng
secret
infant
level
correl
well
symptom
diseas
concentr
infant
present
bronchiol
higher
upper
respiratori
tract
symptomatolog
eosinophil
increas
bronchial
epithelium
biopsi
taken
normal
asthmat
human
volunt
follow
experiment
rv
infect
small
studi
eosinophil
inflamm
persist
week
asthmat
subject
allerg
rhinit
subject
experiment
rv
infect
increas
bal
eosinophil
follow
segment
allergen
challeng
effect
similarli
persist
week
increas
level
eosinophil
cation
protein
found
sputum
rvinfect
subject
eosinophil
accumul
airway
influenc
gmcsf
rant
eotaxin
express
potent
eosinophil
chemoattract
rant
increas
nasal
secret
children
natur
virusinduc
asthma
exacerb
primari
nasal
epitheli
cell
cultur
rsv
rv
gmcsf
believ
import
eosinophil
product
bone
marrow
prolong
eosinophil
surviv
howev
level
appear
increas
viral
upper
respiratori
tract
infect
level
eotaxin
nasal
lavag
rise
experiment
infect
data
suggest
pathogen
role
eosinophil
virusinduc
asthma
howev
protect
role
also
possibl
allerg
rhinit
subject
infect
rv
highdos
allergen
challeng
sever
durat
cold
symptom
invers
relat
nasal
lavag
eosinophil
count
prior
infect
eosinophil
may
contribut
antigen
present
viru
infect
eosinophil
purifi
pbmc
pretreat
gmcsf
bind
via
present
viral
antigen
cell
induc
prolifer
secret
ifnc
eosinophil
antivir
action
parainfluenzainfect
guinea
pig
eosinophilderiv
neurotoxin
cation
protein
ribonucleas
activ
reduc
rsv
infect
role
eosinophil
antivir
immun
respons
thu
requir
evalu
neutrophil
recruit
earli
viral
infect
respons
product
chemokin
epitheli
cell
activ
neutrophil
promin
featur
sever
asthma
induc
sputum
studi
asthmat
nonasthmat
volunt
demonstr
signific
increas
sputum
neutrophil
day
natur
cold
correl
sputum
similar
result
obtain
induc
sputum
taken
day
experiment
infect
asthmat
subject
intracellular
stain
demonstr
increas
cell
posit
day
could
attribut
increas
neutrophil
chemokin
potent
chemoattract
neutrophil
also
act
lymphocyt
basophil
prime
eosinophil
increas
found
nasal
lavag
children
natur
cold
experiment
infect
atop
asthmat
result
elev
nasal
lavag
correl
cold
asthma
symptom
score
fall
histamin
sputum
asthmat
asthma
exacerb
elev
neutrophilia
studi
experiment
virusinduc
asthma
children
also
demonstr
elev
neutrophilia
nasal
aspir
acut
phase
infect
level
neutrophil
myeloperoxidas
correl
symptom
sever
studi
suggest
promin
role
neutrophil
tissu
damag
virusinduc
asthma
natur
killer
cell
nk
cell
import
part
innat
immun
respons
function
elimin
varieti
target
cell
includ
virusinfect
cell
modul
adapt
immun
toward
virus
cell
kill
nk
cell
may
occur
natur
kill
antibodydepend
cellular
cytotox
adcc
apoptot
kill
fasposit
target
cell
via
membran
bound
fasl
abil
directli
kill
virusinfect
cell
regul
balanc
inhibitori
activ
receptor
killer
inhibitori
receptor
kir
iglik
receptor
recogn
hlaa
b
c
molecul
lectinlik
receptor
interact
hlae
allow
nk
cell
recogn
cell
express
normal
self
mhc
class
loss
inhibit
occur
potenti
target
cell
lost
class
express
follow
viru
infect
display
abnorm
class
ipeptid
complex
nk
cell
rapid
effici
produc
cytokin
ifnc
import
earli
viral
infect
antigenindepend
activ
antigenpres
cell
macrophag
dendrit
cell
epitheli
cell
bias
develop
cell
function
nk
cell
asthmat
airway
yet
unexplor
may
airway
environ
rich
type
cytokin
nk
type
function
effect
antivir
activ
inhibit
case
key
compon
earli
immun
respons
would
defici
viral
clearanc
would
impair
elev
serum
total
allergenspecif
ige
featur
extrins
atop
asthma
igemedi
mechan
certainli
import
pathophysiolog
extrins
asthma
recent
studi
suggest
similar
airway
patholog
extrins
intrins
nonatop
asthma
absenc
specif
serum
ige
neg
skin
prick
test
aeroallergen
suggest
may
product
local
ige
yet
unknown
environment
allergen
intrins
asthma
upregul
total
ige
virusallergenspecif
ige
local
system
respiratori
viru
infect
would
expect
contribut
durat
sever
symptom
asthma
exacerb
intranas
challeng
result
increas
total
serum
ige
allerg
rhinit
subject
increas
preexist
allergenspecif
ige
children
asthma
infect
influenza
chang
total
ige
increas
observ
specif
serum
ige
hous
dust
mite
exvivo
prolif
respons
lymphocyt
challeng
hous
dust
mite
allergen
studi
rsv
infect
infant
develop
serum
rsvspecif
ige
occur
frequent
atop
correl
clinic
wheez
histamin
level
nasal
secret
hypoxia
inform
yet
presenc
local
virusspecif
ige
airway
asthma
exacerb
increas
interest
clinic
featur
pathogenesi
copd
reflect
worldwid
import
diseas
million
patient
affect
unit
state
alon
predict
becom
third
lead
caus
death
worldwid
nation
global
initi
launch
manag
guidelin
publish
frequenc
exacerb
major
factor
qualiti
life
patient
copd
problem
exist
defin
acut
exacerb
one
definit
acut
tracheobronch
gener
infecti
etiolog
occur
patient
establish
copd
import
element
definit
caus
respiratori
deterior
frequent
encount
patient
group
congest
cardiac
failur
cardiac
arrhythmia
pneumothorax
pneumonia
pulmonari
thromboembol
must
exclud
typic
clinic
featur
exacerb
includ
increas
dyspnea
wheez
cough
sputum
product
worsen
ga
exchang
although
noninfecti
caus
exacerb
allergi
air
pollut
inhal
irrit
includ
cigarett
smoke
may
import
acut
airway
infect
major
precipit
infect
consequ
host
inflammatori
respons
result
increas
airway
obstruct
least
third
exacerb
may
caus
viral
infect
studi
patient
rhinovirus
influenza
viru
parainfluenza
viru
coronaviru
significantli
associ
copd
exacerb
patient
seem
increas
suscept
virus
viral
infect
seriou
consequ
occur
role
bacteria
precipit
exacerb
controversi
bacteria
may
primari
role
develop
exacerb
repres
secondari
superinfect
initi
viral
process
variou
bacteri
speci
present
airway
patient
even
copd
stabl
increas
frequenc
recoveri
bacteria
exacerb
suggest
play
role
signific
bacteri
infect
suggest
abund
neutrophil
sputum
sputum
purul
green
due
neutrophil
myeloperoxidas
major
bacteri
organ
associ
copd
exacerb
nontyp
haemophili
influenza
streptococcu
pneumonia
moraxella
branhamella
catarrhali
mycoplasma
pneumonia
chlamydia
pneumonia
may
play
part
evid
also
suggest
sever
patient
baselin
fev
predict
less
gramneg
bacteria
especi
enterobacteriacea
pseudomona
play
import
part
acut
exacerb
although
result
placebocontrol
trial
show
conflict
result
overal
effect
antibiot
treatment
also
suggest
etiolog
role
bacteria
exacerb
patient
metaanalysi
nine
studi
show
small
overal
benefit
antibiot
use
copd
exacerb
largest
studi
includ
exacerb
outpati
compar
placebo
rate
symptom
resolut
improv
peak
expiratori
flow
exacerb
slightli
significantli
faster
patient
treat
cotrimoxazol
amoxicillin
doxycyclin
importantli
treatment
failur
defin
respiratori
deterior
nearli
twice
like
placebo
group
benefit
antibiot
evid
patient
symptom
dyspnea
increas
sputum
volum
sputum
purul
guidelin
use
antibiot
acut
exacerb
copd
unclear
difficulti
defin
role
bacteri
infect
individu
case
american
thorac
societi
statement
copd
suggest
use
antibiot
evid
infect
fever
leukocytosi
cxr
chang
patient
bacteri
bronchial
infect
fever
common
viral
infect
pneumonia
cxr
chang
european
respiratori
societi
recommend
antibiot
sputum
purul
use
standard
antibiot
first
line
sputum
cultur
fail
major
bacteri
pathogen
isol
bronchial
infect
form
part
commens
flora
nasopharynx
bronchial
infect
occur
patient
abnorm
airway
reduc
host
defens
persist
bacteria
within
bronchial
tree
may
come
toxin
impair
mucociliari
clearanc
enzym
break
local
immunoglobulin
product
alter
immun
effector
cell
function
adher
mucou
damag
epithelium
mechan
avoid
immun
surveil
bronchial
infect
usual
remain
confin
mucosa
mani
resolv
spontan
without
antibiot
treatment
persist
bacteri
infect
usual
reflect
sever
impair
lung
defens
rather
virul
microorgan
damag
lung
tissu
caus
host
inflammatori
respons
chronic
bacteri
infect
may
import
damag
caus
directli
bacteria
bacteri
infect
definit
role
pathogenesi
chronic
lung
diseas
cystic
fibrosi
bronchiectasi
bacteri
infect
chronic
caus
acut
exacerb
also
influenc
longterm
prognosi
diseas
chronic
bacteri
infect
set
viciou
cycl
host
inflammatori
respons
unabl
clear
bacteria
instead
promot
continu
infect
tissu
damag
neutrophil
produc
proteinas
reactiv
oxygen
speci
lung
antiproteinas
defens
overwhelm
proteinas
enzym
reactiv
oxygen
speci
caus
damag
epithelium
stimul
mucou
product
impair
mucociliari
clearanc
neutrophil
elastas
stimul
epitheli
cell
product
chemokin
attract
neutrophil
addit
impair
phagocytosi
destroy
antibodi
cleav
complement
receptor
neutrophil
complement
compon
bacteria
similar
cellular
mechan
oper
copd
neutrophil
also
stimul
cigarett
smoke
copd
patient
may
chronic
colon
bacteria
exacerb
bacteri
number
increas
exacerb
studi
use
bronchoscop
protect
brush
specimen
ten
copd
patient
colon
bacteria
stabl
exacerb
bacteria
present
present
bacteri
number
greaterwhen
protect
brush
specimen
taken
sever
acut
exacerb
copd
requir
ventil
bacteria
detect
possibl
distinguish
patient
like
bacteria
basi
clinic
featur
investig
bacteri
colon
stabl
state
repres
equilibrium
number
bacteria
present
bronchial
tree
contain
host
defens
elimin
exacerb
equilibrium
upset
bacteri
number
increas
incit
inflammatori
respons
chang
usual
occur
chang
host
rather
alter
virul
bacteria
exampl
result
viral
infect
mani
exacerb
copd
occur
without
hallmark
bacteri
infect
increas
volum
purul
sputum
exacerb
associ
symptom
common
cold
frequenc
exacerb
requir
hospit
higher
winter
one
explan
could
increas
frequenc
respiratori
virus
time
year
recent
studi
exacerb
patient
moder
sever
copd
use
new
diagnost
method
includ
rtpcr
show
high
incid
viral
infect
virus
detect
nasal
aspir
exacerb
almost
case
rhinoviru
common
occur
case
viru
present
presenc
viru
associ
increas
dyspnea
cold
symptom
sore
throat
prolong
recoveri
exacerb
earlier
studi
reli
serolog
viru
cultur
quot
lower
viru
detect
rate
suggest
persist
viru
infect
contribut
progress
copd
particular
adenoviru
appear
persist
latent
form
viral
protein
produc
without
replic
complet
viru
latent
infect
may
amplifi
lung
inflamm
due
cigarett
smoke
adenovir
dna
persist
human
lung
patient
copd
compar
patient
similar
age
sex
smoke
histori
copd
protein
demonstr
airway
epitheli
cell
smoker
abl
amplifi
mani
host
gene
attach
dnabind
site
transcript
factor
airway
epitheli
cell
transfect
produc
excess
inflammatori
cytokin
surfac
adhes
molecul
invitro
challeng
nfjbdepend
mechan
rsv
identifi
induc
sputum
patient
stabl
copd
individu
higher
plasma
fibrinogen
serum
higher
pco
increas
frequenc
exacerb
suggest
either
low
grade
persist
rsv
infect
contribut
copd
sever
patient
sever
copd
less
abl
clear
rsv
airway
immunolog
viru
infect
copd
well
understood
fewer
data
avail
viru
infect
asthma
sinc
subject
human
experiment
infect
studi
studi
clearli
need
view
increas
evid
major
role
virus
caus
copd
exacerb
current
much
treatment
infect
exacerb
asthma
copd
symptomat
consist
increas
bronchodil
support
form
oxygen
sever
case
noninvas
invas
ventilatori
measur
corticosteroid
wide
use
inhal
oral
form
antiinflammatori
action
major
role
asthma
also
effect
mani
infect
exacerb
copd
even
patient
stabl
show
littl
evid
steroid
responsivenessth
effect
corticosteroid
result
action
mani
point
variou
inflammatori
cascad
whilst
undoubtedli
contribut
benefici
effect
also
result
signific
sideeffect
particular
system
steroid
treatment
prolong
frequent
addit
system
steroid
may
interfer
antivir
immun
respons
result
reduc
viral
clearanc
specif
antibiot
therapi
avail
bacteri
infect
indic
good
evid
infect
exacerb
sever
bacteri
involv
possibl
howev
discuss
major
infect
asthma
exacerb
viral
rather
bacteri
origin
virus
also
common
exacerb
copd
success
vaccin
prevent
respiratori
viru
infect
limit
signific
variat
within
major
viru
type
caus
diseas
serotyp
rhinoviru
effect
vaccin
introduc
influenza
virus
display
antigen
shift
drift
new
vaccin
must
develop
everi
year
cover
strain
preval
time
new
pandem
strain
aris
delay
suffici
quantiti
vaccin
made
avail
spite
problem
combin
influenza
vaccin
valu
individu
chronic
respiratori
diseas
especi
elderli
vaccin
rsv
experienc
major
setback
use
formalininactiv
viru
young
babi
result
increas
diseas
sever
follow
subsequ
viru
infect
two
main
approach
therapi
viral
exacerb
first
use
antivir
agent
direct
action
viru
larg
number
virus
produc
similar
clinic
syndrom
use
specif
antivir
drug
requir
rapid
accur
diagnost
method
pcr
second
approach
identifi
key
compon
antivir
immun
respons
design
drug
either
enhanc
benefici
antivir
aspect
immun
respons
inhibit
compon
lead
immunopatholog
understand
complex
antivir
immun
respons
particular
may
alter
context
preexist
chronic
airway
diseas
asthma
copd
essenti
first
step
simpl
nonspecif
treatment
common
cold
exist
although
efficaci
debat
vitamin
c
zinc
glucon
may
shorten
durat
cold
day
inhal
humidifi
hot
air
provid
symptomat
relief
nasal
ifna
effect
treatment
common
cold
must
given
either
prior
shortli
exposur
viru
also
expens
associ
signific
local
sideeffect
bleed
discharg
problem
limit
clinic
use
amantadin
rimantadin
effect
influenza
inhibit
viral
ion
channel
import
uncoat
releas
viru
genom
host
cell
use
amantadin
limit
cn
sideeffect
dizzi
insomnia
fewer
sideeffect
seen
rimantadin
drug
indic
use
epidem
influenza
treatment
prophylaxi
highrisk
group
includ
patient
asthma
copd
neither
activ
influenza
b
two
new
neuraminidas
inhibitor
zanamivir
oseltamivir
activ
influenza
b
agent
effect
prevent
infect
use
prophylaxi
influenza
season
treatment
reduc
durat
ill
day
start
within
hour
onset
ill
zanamivir
must
given
inhal
wherea
oseltamivir
given
oral
ribavarin
nucleosid
analogu
activ
rsv
vivo
also
influenza
vitro
oral
prepar
limit
benefit
influenza
due
rapid
metabol
inhal
ribavirin
may
effect
reduc
symptom
viral
shed
toxic
appropri
asthma
copd
use
restrict
infant
children
first
day
rsv
bronchiol
rsvenrich
immunoglobulin
effect
prophylaxi
infant
high
risk
rsv
bronchiol
trial
rsv
neutral
monoclon
antibodi
progress
therapi
indic
patient
asthma
copd
rhinovirus
major
target
drug
treatment
estim
rhinovirus
result
six
ten
cold
per
year
young
children
two
five
per
year
adult
yet
effect
agent
avail
clinic
use
capsid
bindingcanyon
inhibitor
block
bind
rhinovirus
host
cell
receptor
case
major
group
drug
extrem
potent
clinic
use
limit
serotyp
specif
rapid
develop
resist
altern
target
includ
solubl
inhibit
major
rhinoviru
infect
vitro
conserv
viral
enzym
protein
rnadepend
rna
transcriptas
protein
associ
atphelicas
cystein
proteas
infect
particular
respiratori
virus
common
trigger
exacerb
asthma
copd
knowledg
mechan
virusinduc
exacerb
remain
incomplet
case
asthma
investig
interact
preexist
asthmat
airway
inflamm
antivir
immun
respons
viru
infect
allergen
exposur
further
use
model
experiment
rhinoviru
infect
human
volunt
similar
studi
requir
copd
exacerb
fewer
data
current
avail
current
therapi
virusinduc
exacerb
asthma
copd
reli
increas
treatment
preexist
diseas
corticosteroid
form
major
antiinflammatori
compon
therapi
use
associ
signific
sideeffect
especi
use
system
high
dose
antibiot
indic
bacteri
infect
antivir
agent
exist
particular
influenza
virus
effect
use
drug
asthma
copd
requir
viral
diagnosi
commenc
treatment
earli
cours
exacerb
target
highrisk
group
prophylaxi
clinic
effect
broad
spectrum
agent
yet
avail
rhinovirus
common
caus
exacerb
altern
strategi
drug
develop
may
involv
identif
key
factor
common
exacerb
induc
rang
differ
virus
increas
knowledg
hostviru
interact
requir
design
treatment
increas
viru
clearanc
minim
immunopatholog
